Efficacy of Direct-Acting Antiviral Combination for Patients with Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

© 2016 AGA Institute. Background & Aims Although hepatitis C virus (HCV) infection is common in patients with end-stage renal disease, highly efficacious, well-tolerated, direct-acting antiviral regimens have not been extensively studied in this population. We investigated the safety and efficacy of ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir (with or without ribavirin) in a prospective study of patients with stage 4 or 5 chronic kidney disease (CKD). Methods We performed a single-arm, multicenter study of treatment-naïve adults with HCV genotype 1 infection, without cirrhosis and with CKD stage 4 (estimated glomerular filtration rate, 15-30 mL/min/1.73 m2) or stage 5 (estimated glomerular filtration rate, /min/1.73 m2or requiring hemodialysis). Twenty patients were given ombitasvir co-formulated with paritaprevir and ritonavir, administered with dasabuvir for 12 weeks. Patients with HCV genotype 1a infections also received ribavirin (n = 13), whereas those with genotype 1b infection did not (n = 7). The primary end point was sustained virologic response (serum HCV RNA /mL) 12 weeks after treatment ended (SVR12). We collected data on on-treatment adverse events (AEs), serious AEs, and laboratory abnormalities. Results All 20 patients completed 12 weeks of treatment. Eighteen of the 20 patients achieved SVR12 (90%; 95% confidence interval: 69.9-97.2). One patient death after the end of the treatment (unrelated to the treatment) and 1 relapse accounted for the 2 non-SVRs. Adverse events were primarily mild or moderate, and no patient discontinued treatment due to an AE. Four patients experienced serious AEs; all were considered unrelated to treatment. Ribavirin therapy was interrupted in 9 patients due to anemia; 4 received erythropoietin. No blood transfusions were performed. Conclusions In a clinical trial, the combination of ombitasvir, paritaprevir, and ritonavir, administered with dasabuvir, led to an SVR12 in 90% of patients with HCV genotype 1 infection and stage 4 or 5 CKD. The regimen is well tolerated, though RBV use may require a reduction or interruption to manage anemia. ClinicalTrials.gov ID NCT02207088

Forward Jets and Energy Flow in Hadronic Collisions

We observe that at the Large Hadron Collider, using forward + central detectors, it becomes possible for the first time to carry out calorimetric measurements of the transverse energy flow due to "minijets" accompanying production of two jets separated by a large rapidity interval. We present parton-shower calculations of energy flow observables in a high-energy factorized Monte Carlo framework, designed to take into account QCD logarithmic corrections both in the large rapidity interval and in the hard transverse momentum. Considering events with a forward and a central jet, we examine the energy flow in the interjet region and in the region away from the jets. We discuss the role of these observables to analyze multiple parton collision effects.Comment: 9 pages, 5 figures. Version2: added results on azimuthal distributions and more discussion of energy flow definition using jet clusterin

The prevalence and incidence of mental ill-health in adults with autism and intellectual disabilities

The prevalence, and incidence, of mental ill-health in adults with intellectual disabilities and autism were compared with the whole population with intellectual disabilities, and with controls, matched individually for age, gender, ability-level, and Down syndrome. Although the adults with autism had a higher point prevalence of problem behaviours compared with the whole adult population with intellectual disabilities, compared with individually matched controls there was no difference in prevalence, or incidence of either problem behaviours or other mental ill-health. Adults with autism who had problem behaviours were less likely to recover over a two-year period than were their matched controls. Apparent differences in rates of mental ill-health are accounted for by factors other than autism, including Down syndrome and ability level

Factorization and resummation of s-channel single top quark production

In this paper we study the factorization and resummation of s-channel single top quark production in the Standard Model at both the Tevatron and the LHC. We show that the production cross section in the threshold limit can be factorized into a convolution of hard function, soft function and jet function via soft-collinear-effective-theory (SCET), and resummation can be performed using renormalization group equation in the momentum space resummation formalism. We find that in general, the resummation effects enhance the Next-to-Leading-Order (NLO) cross sections by about $3$ at both the Tevatron and the LHC, and significantly reduce the factorization scale dependence of the total cross section at the Tevatron, while at the LHC we find that the factorization scale dependence has not been improved, compared with the NLO results.Comment: 29 pages, 7 figures; version published in JHE

Strong Phases and Factorization for Color Suppressed Decays

We prove a factorization theorem in QCD for the color suppressed decays B0-> D0 M0 and B0-> D*0 M0 where M is a light meson. Both the color-suppressed and W-exchange/annihilation amplitudes contribute at lowest order in LambdaQCD/Q where Q={mb, mc, Epi}, so no power suppression of annihilation contributions is found. A new mechanism is given for generating non-perturbative strong phases in the factorization framework. Model independent predictions that follow from our results include the equality of the B0 -> D0 M0 and B0 -> D*0 M0 rates, and equality of non-perturbative strong phases between isospin amplitudes, delta(DM) = delta(D*M). Relations between amplitudes and phases for M=pi,rho are also derived. These results do not follow from large Nc factorization with heavy quark symmetry.Comment: 38 pages, 6 figs, typos correcte

Factorization Theorem For Drell-Yan At Low q_T And Transverse-Momentum Distributions On-The-Light-Cone

We derive a factorization theorem for Drell-Yan process at low q_T using effective field theory methods. In this theorem all the obtained quantities are gauge invariant and the special role of the soft function--and its subtraction thereof--is emphasized. We define transverse-momentum dependent parton distribution functions (TMDPDFs) which are free from light-cone singularities while all the Wilson lines are defined on-the-light-cone. We show explicitly to first order in \alpha_s that the partonic Feynman PDF can be obtained from the newly defined partonic TMDPDF by integrating over the transverse momentum of the parton inside the hadron. We obtain a resummed expression for the TMDPDF, and hence for the cross section, in impact parameter space. The universality of the newly defined matrix elements is established perturbatively to first order in \alpha_s. The factorization theorem is validated to first order in \alpha_s and also the gauge invariance between Feynman and light-cone gauges.Comment: Minor changes. Version published in JHE

Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial.

Severe alcoholic hepatitis (sAH) is associated with a poor prognosis. There is no proven effective treatment for sAH, which is why early transplantation has been increasingly discussed. Hepatoblastoma-derived C3A cells express anti-inflammatory proteins and growth factors and were tested in an extracorporeal cellular therapy (ELAD) study to establish their effect on survival for subjects with sAH. Adults with sAH, bilirubin ≥8 mg/dL, Maddrey\u27s discriminant function ≥ 32, and Model for End-Stage Liver Disease (MELD) score ≤ 35 were randomized to receive standard of care (SOC) only or 3-5 days of continuous ELAD treatment plus SOC. After a minimum follow-up of 91 days, overall survival (OS) was assessed by using a Kaplan-Meier survival analysis. A total of 203 subjects were enrolled (96 ELAD and 107 SOC) at 40 sites worldwide. Comparison of baseline characteristics showed no significant differences between groups and within subgroups. There was no significant difference in serious adverse events between the 2 groups. In an analysis of the intent-to-treat population, there was no difference in OS (51.0% versus 49.5%). The study failed its primary and secondary end point in a population with sAH and with a MELD ranging from 18 to 35 and no upper age limit. In the prespecified analysis of subjects with MELD \u3c 28 (n = 120), ELAD was associated with a trend toward higher OS at 91 days (68.6% versus 53.6%; P = .08). Regression analysis identified high creatinine and international normalized ratio, but not bilirubin, as the MELD components predicting negative outcomes with ELAD. A new trial investigating a potential benefit of ELAD in younger subjects with sufficient renal function and less severe coagulopathy has been initiated. Liver Transplantation 24 380-393 2018 AASLD

Nonfactorizable contributions to B→D(∗)MB \to D^{(*)} M decays

While the factorization assumption works well for many two-body nonleptonic $B$ meson decay modes, the recent measurement of $\bar B\to D^{(*)0}M^0$ with $M=\pi$, $\rho$ and $\omega$ shows large deviation from this assumption. We analyze the $B\to D^{(*)}M$ decays in the perturbative QCD approach based on $k_T$ factorization theorem, in which both factorizable and nonfactorizable contributions can be calculated in the same framework. Our predictions for the Bauer-Stech-Wirbel parameters, $|a_2/a_1|= 0.43\pm 0.04$ and $Arg(a_2/a_1)\sim -42^\circ$ and $|a_2/a_1|= 0.47\pm 0.05$ and $Arg(a_2/a_1)\sim -41^\circ$, are consistent with the observed $B\to D\pi$ and $B\to D^*\pi$ branching ratios, respectively. It is found that the large magnitude $|a_2|$ and the large relative phase between $a_2$ and $a_1$ come from color-suppressed nonfactorizable amplitudes. Our predictions for the ${\bar B}^0\to D^{(*)0}\rho^0$, $D^{(*)0}\omega$ branching ratios can be confronted with future experimental data.Comment: 25 pages with Latex, axodraw.sty, 6 figures and 5 tables, Version published in PRD, Added new section 5 and reference

A Formalism for the Systematic Treatment of Rapidity Logarithms in Quantum Field Theory

Many observables in QCD rely upon the resummation of perturbation theory to retain predictive power. Resummation follows after one factorizes the cross section into the rele- vant modes. The class of observables which are sensitive to soft recoil effects are particularly challenging to factorize and resum since they involve rapidity logarithms. In this paper we will present a formalism which allows one to factorize and resum the perturbative series for such observables in a systematic fashion through the notion of a "rapidity renormalization group". That is, a Collin-Soper like equation is realized as a renormalization group equation, but has a more universal applicability to observables beyond the traditional transverse momentum dependent parton distribution functions (TMDPDFs) and the Sudakov form factor. This formalism has the feature that it allows one to track the (non-standard) scheme dependence which is inherent in any scenario where one performs a resummation of rapidity divergences. We present a pedagogical introduction to the formalism by applying it to the well-known massive Sudakov form factor. The formalism is then used to study observables of current interest. A factorization theorem for the transverse momentum distribution of Higgs production is presented along with the result for the resummed cross section at NLL. Our formalism allows one to define gauge invariant TMDPDFs which are independent of both the hard scattering amplitude and the soft function, i.e. they are uni- versal. We present details of the factorization and resummation of the jet broadening cross section including a renormalization in pT space. We furthermore show how to regulate and renormalize exclusive processes which are plagued by endpoint singularities in such a way as to allow for a consistent resummation.Comment: Typos in Appendix C corrected, as well as a typo in eq. 5.6